US-based biotechnology firm Genzyme has provided an extensive briefing of its alemtuzumab medication, used in the treatment of multiple sclerosis.

The company defined the unmet demands for multiple sclerosis treatments using third-party analysis and market research, before announcing that alemtuzumab may address these needs.

Research conducted by the company supports forecasts for adoption of the medication, with anticipated peak sales figures between $3-3.5bn.

Genzyme is conducting two Phase III trials in order to evaluate the medications efficacy in the treatment of multiple sclerosis, comparing alemtuzumab to Rebif, and the company expects results in mid-2011 before filing for US and EU approval in early 2012.